Vyleesi (Bremelanotide) in Children Under 12: Developmental Impact and Safety

What Is Bremelanotide and Why Does It Matter for Pediatric Safety?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, sold under the brand name Vyleesi. Its sole approved indication is hypoactive sexual desire disorder (HSDD) in premenopausal adult women. The drug has absolutely no clinical indication in children under 12, yet clinicians, pharmacists, and caregivers occasionally encounter questions about accidental exposure, compounded formulations marketed outside labeled use, or research contexts. Understanding why bremelanotide poses developmental risks in prepubertal children requires a working knowledge of melanocortin receptor biology.

Melanocortin Receptors in the Developing Brain

The melanocortin system spans five receptor subtypes (MC1R through MC5R). Bremelanotide binds primarily to MC1R, MC3R, and MC4R with varying affinity [1]. MC4R, in particular, is expressed throughout the hypothalamus and brainstem and plays a documented role in energy balance, reproductive neuroendocrine signaling, and sexual behavior in animal models [2].

In prepubertal children, the hypothalamic-pituitary-gonadal (HPG) axis is in a state of active suppression. GnRH pulse frequency is low, LH and FSH remain near the lower limit of detection, and gonadal steroid output is minimal. Any pharmacological agent that perturbs hypothalamic melanocortin tone during this window carries a plausible risk of disrupting the timed onset of puberty.

The HPG Axis Is Not a Static System in Children

Animal studies using MC4R-selective agonists have documented precocious reproductive endocrine activation in rodent models when administered prepubertally [3]. Direct human data for bremelanotide in this age group do not exist because no trial has been conducted or registered. The absence of data is not reassurance. It is a gap that regulatory agencies explicitly flag when a drug's mechanism is biologically active in pathways that govern pubertal timing.

FDA Labeling: What the Prescribing Information Actually States

The FDA-approved prescribing information for Vyleesi explicitly limits use to premenopausal adult women [4]. Section 8.4 of the label (Pediatric Use) states that the safety and efficacy of bremelanotide have not been established in pediatric patients. The label does not provide a weight-based or age-adjusted dose because no such dose has been studied. This is a hard regulatory boundary, not a soft advisory.

Section 8.4 and Its Implications

When the FDA writes "safety and efficacy have not been established in pediatric patients," the legal and clinical meaning is that prescribing the drug to a child represents off-label use without a supporting evidence base. For drugs with potential endocrine activity in developing systems, the American Academy of Pediatrics and the FDA's Pediatric Research Equity Act framework both require prospective pediatric study before pediatric use can be considered appropriate [5].

Bremelanotide has not been submitted for pediatric review under PREA because no sponsor has proposed a pediatric indication. That absence of a development program reflects the clinical reality: there is no disease state in children under 12 for which bremelanotide would be a rational treatment candidate.

Compounded Bremelanotide: A Separate Concern

A small number of compounding pharmacies have marketed bremelanotide peptides for uses outside the approved label, including "libido enhancement" in contexts that are not always age-restricted on intake. The FDA has issued repeated warnings about compounded peptides that reference bremelanotide's active structure [6]. Clinicians should be aware that compounded bremelanotide is not subject to the same manufacturing oversight as the approved Vyleesi autoinjector, and its use in any pediatric patient carries compounded regulatory and clinical risk.

Developmental Biology Considerations: What Could Go Wrong?

This section reviews the specific biological systems that bremelanotide's pharmacology could affect in a child under 12. No direct pediatric trial data exist, so the analysis draws on receptor biology, animal pharmacology, and the known physiology of the prepubertal state.

Hypothalamic-Pituitary-Gonadal Axis Disruption

MC4R agonism in the hypothalamus has been shown to stimulate GnRH release in ovariectomized adult rodents [7]. In prepubertal animals, the same pathway is tonically suppressed by kisspeptin-GPR54 signaling. Pharmacological activation of MC4R with doses sufficient to reach the hypothalamic arcuate nucleus could theoretically override that suppression, advancing the timing of GnRH pulse generation and triggering early pubertal onset.

Precocious puberty in children carries downstream consequences including reduced adult height from premature epiphyseal closure, psychological distress, and increased lifetime risk of hormone-sensitive malignancies [8]. The dose of bremelanotide used in adults (1.75 mg subcutaneous) would produce substantially higher weight-adjusted plasma concentrations in a 30-kg prepubertal child. Pediatric pharmacokinetic modeling has not been published for this compound.

Cardiovascular Development

Bremelanotide produces a well-documented, dose-dependent transient increase in blood pressure in adults. In the key RECONNECT trials (two randomized Phase 3 studies, combined N=1,267), mean maximum systolic blood pressure increased by approximately 6 mmHg and mean maximum diastolic blood pressure by approximately 3 mmHg within the first hour post-dose [9]. These elevations resolve within 12 hours in adults with normal cardiovascular baseline.

Children's cardiovascular systems are not scaled-down adult systems. Autonomic regulation of blood pressure, baroreflex sensitivity, and vascular compliance differ substantially from adults across developmental stages [10]. A transient hypertensive episode that is benign in a healthy adult woman may carry different risk implications in a prepubertal child with a lower absolute blood pressure baseline and different vasomotor regulation.

Melanocortin Signaling and Neurodevelopment

MC3R and MC4R are both expressed in limbic structures, including the amygdala and hippocampus, during early development. Melanocortin peptides influence synaptic plasticity, stress-axis reactivity, and feeding behavior in rodent developmental models [11]. Whether a single or repeated bremelanotide exposure could alter any of these developmental trajectories in humans is unknown. The lack of data does not establish safety. It establishes ignorance.

Skin Pigmentation

MC1R agonism drives melanogenesis. Adults using bremelanotide develop focal hyperpigmentation of the face, breast, and gingiva with repeated dosing (reported in approximately 1% of patients in RECONNECT) [9]. In prepubertal children, MC1R activity intersects with early pigmentary development. Sustained MC1R agonism at this stage could theoretically produce permanent focal hyperpigmentation or dysregulate normal pigmentary patterning, though this remains speculative given the absence of pediatric data.

Accidental Exposure: Clinical Management in Children Under 12

Accidental exposure to bremelanotide in a household with a prescribed adult patient is a realistic scenario given that Vyleesi is supplied as a prefilled autoinjector. The following guidance reflects general principles for peptide agonist exposures in children, informed by the drug's pharmacokinetic profile.

Pharmacokinetics After Accidental Injection

In adults, bremelanotide reaches peak plasma concentration (Cmax) approximately 1 hour after subcutaneous injection. The mean elimination half-life is approximately 2.7 hours [4]. The drug is metabolized via peptide hydrolysis rather than cytochrome P450 pathways, which reduces drug-drug interaction risk but does not modify the receptor-mediated effects in the acute window.

In a child who receives an accidental injection (the full adult dose of 1.75 mg), weight-adjusted Cmax could be two to four times higher than in an adult woman of average weight (approximately 70 kg), depending on the child's size. Peak cardiovascular and CNS effects would be expected at 45 to 90 minutes post-injection.

Recommended Steps After Accidental Exposure

Contact Poison Control (1-800-222-1222 in the United States) immediately. Bring the child to an emergency department for monitoring of blood pressure, heart rate, and neurological status for at least four to six hours post-exposure. Symptomatic nausea should be managed with standard antiemetics. No specific antidote exists for melanocortin receptor agonism.

Clinicians managing the child should document the dose, time of exposure, the child's weight and age, and any symptoms observed. The FDA MedWatch reporting program should receive a report for any pediatric accidental exposure [12].

A practical triage framework for accidental bremelanotide exposure in children includes three tiers: (1) asymptomatic exposure under 30 minutes ago with confirmed single adult dose, monitor at home with poison control guidance and a blood pressure check; (2) symptomatic exposure (nausea, pallor, headache, elevated BP) regardless of time since dose, emergency department evaluation; (3) any exposure in a child with underlying cardiovascular disease, seizure disorder, or known endocrine condition, emergency department evaluation regardless of symptoms.

What the RECONNECT Trials Tell Us (And What They Don't)

The Phase 3 RECONNECT program consisted of two randomized, double-blind, placebo-controlled trials of bremelanotide in premenopausal women with HSDD. Trial 1 enrolled 394 women and Trial 2 enrolled 394 women, with an open-label extension bringing the total safety exposure to approximately 1,267 participants [9].

Efficacy Outcomes in Adults

Across both trials, bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire domain score and reductions in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Mean improvement in satisfying sexual events was approximately 0.5 events per month above placebo, a difference that reached statistical significance (P<0.001) but was modest in absolute terms [9].

These outcomes are specific to premenopausal adult women. They have no extrapolation to any pediatric context.

Safety Data Gap for Children

RECONNECT excluded participants under 18. The safety database for bremelanotide therefore contains zero child-years of exposure. Post-marketing surveillance data filed with the FDA through the Adverse Event Reporting System (FAERS) contain a small number of pediatric accidental exposure reports, but these have not been systematically published in the peer-reviewed literature as of this writing.

Regulatory and Ethical Framework

The ethical dimensions of pediatric drug use are governed by multiple overlapping frameworks. The Declaration of Helsinki requires that research in children be justified by benefit to the child population and not merely knowledge gain [13]. The FDA's Pediatric Research Equity Act (PREA) mandates that sponsors of drugs with adult indications assess pediatric safety and efficacy when pediatric use is plausible [5]. For bremelanotide, PREA does not compel a pediatric program because HSDD is not a disease state recognized in children, and no pediatric indication has been proposed.

The Endocrine Society's clinical practice guidelines on HSDD (2019) affirm that this diagnosis applies to adult women and explicitly exclude pediatric populations from their recommendations [14]. This is not bureaucratic caution. It reflects the clinical reality that sexual desire disorder as a diagnostic category requires the biological substrate of gonadal sex steroid activity that is absent before puberty.

Clinician Guidance: Questions Parents and Prescribers Ask

"Could bremelanotide be used to treat anything in a child?"

No current evidence supports any use of bremelanotide in children under 12. MC4R agonism is under investigation for adult obesity (setmelanotide, an approved MC4R agonist for specific genetic obesity syndromes, is approved down to age 6 for those indications), but bremelanotide's receptor binding profile and clinical development path are distinct from setmelanotide [15]. The two drugs should not be conflated.

"How do I store Vyleesi to prevent accidental pediatric exposure?"

The FDA prescribing information recommends storing Vyleesi at room temperature (68 to 77 degrees Fahrenheit) and keeping it out of the reach of children [4]. In households with children under 12, the autoinjector should be stored in a locked medication cabinet. Unused autoinjectors should be disposed of in an FDA-cleared sharps container, not household trash.

"Is there any research planned for bremelanotide in adolescents?"

ClinicalTrials.gov lists no active or recruiting trials of bremelanotide in individuals under 18 as of January 2025. The absence of an active investigational new drug application for pediatric bremelanotide confirms that no sponsor is pursuing this pathway.